Arrowhead Pharmaceuticals Inc  

(Public, NASDAQ:ARWR)   Watch this stock  
Find more results for ARWR
5.57
-0.26 (-4.46%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.46 - 5.95
52 week 1.42 - 6.75
Open 5.85
Vol / Avg. 0.00/2.09M
Mkt cap 483.41M
P/E     -
Div/yield     -
EPS -0.47
Shares 86.79M
Beta 2.52
Inst. own 27%
May 1, 2018
Q2 2018 Arrowhead Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 21, 2018
Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
Mar 16, 2018
Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
Feb 9, 2018
Q1 2018 Arrowhead Pharmaceuticals Inc Earnings Call - Webcast
Feb 9, 2018
Q1 2018 Arrowhead Pharmaceuticals Inc Earnings Release
Jan 8, 2018
Arrowhead Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 12, 2017
Q4 2017 Arrowhead Pharmaceuticals Inc Earnings Call - Webcast
Dec 12, 2017
Q4 2017 Arrowhead Pharmaceuticals Inc Earnings Release
Nov 28, 2017
Arrowhead Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -376.06% -109.46%
Operating margin -393.56% -117.79%
EBITD margin - -102.86%
Return on average assets -55.08% -29.61%
Return on average equity -69.58% -38.85%
Employees 93 -
CDP Score - -

Address

225 S Lake Ave Ste 1050
PASADENA, CA 91101-4820
United States - Map
+1-626-3043400 (Phone)
+1-626-3043401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Officers and directors

Douglass B. Given M.D., Ph.D. Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Christopher Richard Anzalone Ph.D. President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Kenneth Allen Myszkowski Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Bruce D. Given M.D. Chief Operating Officer
Age: 62
Bio & Compensation  - Reuters
Patrick O'Brien General Counsel
Age: 53
Bio & Compensation  - Reuters
Michael S. Perry Ph.D. Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Mauro Ferrari Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Edward W. Frykman Independent Director
Age: 80
Bio & Compensation  - Reuters
William D. Waddill Independent Director
Age: 60
Bio & Compensation  - Reuters